news.today
Hello · Register today | LoginHello · My Account[—] [33]
UK

Oxford trial shows adalimumab could help more NHS uveitis patients

Summarised from 2 outlets · Updated 16 Nov, 06:01 · Archive

A UK trial found adalimumab could protect sight in more uveitis patients than current NHS eligibility rules allow.

A clinical trial led by Oxford University Hospitals and Bristol NHS Foundation Trust has found that the drug adalimumab could protect the sight of more people with uveitis than current NHS eligibility rules allow. The ASTUTE trial involved 18 hospitals across the country and focused on non-infectious uveitis, a rare condition that is a leading cause of blindness in high-income countries.

All trial participants received adalimumab for 16 weeks alongside standard care. Those whose condition improved were then randomly assigned to continue with the drug or switch to a placebo. After one year, 31.4 per cent of patients who continued on adalimumab relapsed or needed further treatment, compared to 59 per cent of those on placebo.

Dr Srilakshmi Sharma, consultant medical ophthalmologist at Oxford Eye Hospital and co-chief investigator of the trial, said: 'We set out to answer a question that patients have been asking us in clinic for years, which is whether this drug would help them if only they were allowed to have it.' She added that the trial provides 'UK trial evidence, from NHS clinics and patients, that the rules are drawn in the wrong place', and called for current NHS eligibility to be expanded.

Oxford trial shows adalimumab could help more NHS uveitis patients
Image: Oxford Mail

Comments (0)

How it is being reported

In this story: adalimumab · Oxford University Hospitals · Bristol NHS Foundation Trust · Oxford Eye Hospital · Dr Srilakshmi Sharma

This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem · Corrections log